Marrachelli Vannina González, Mastronardi Maria Letizia, Sarr Mamadou, Soleti Raffaella, Leonetti Daniela, Martínez María Carmen, Andriantsitohaina Ramaroson
LUNAM Université, Angers, France.
PLoS One. 2013 Aug 16;8(8):e72861. doi: 10.1371/journal.pone.0072861. eCollection 2013.
Microparticles are small fragments of the plasma membrane generated after cell stimulation. We recently showed that Sonic hedgehog (Shh) is present in microparticles generated from activated/apoptotic human T lymphocytes and corrects endothelial injury through nitric oxide (NO) release. This study investigates whether microparticles bearing Shh correct angiotensin II-induced hypertension and endothelial dysfunction in mice. Male Swiss mice were implanted with osmotic minipumps delivering angiotensin II (0.5 mg/kg/day) or NaCl (0.9%). Systolic blood pressure and heart rate were measured daily during 21 days. After 7 day of minipump implantation, mice received i.v. injections of microparticles (10 µg/ml) or i.p. Shh receptor antagonist cyclopamine (10 mg/kg/2 days) during one week. Angiotensin II induced a significant rise in systolic blood pressure without affecting heart rate. Microparticles reversed angiotensin II-induced hypertension, and cyclopamine prevented the effects of microparticles. Microparticles completely corrected the impairment of acetylcholine- and flow-induced relaxation in vessels from angiotensin II-infused mice. The improvement of endothelial function induced by microparticles was completely prevented by cyclopamine treatment. Moreover, microparticles alone did not modify NO and O2 . (-) production in aorta, but significantly increased NO and reduced O2. (-) productions in aorta from angiotensin II-treated mice, and these effects were blocked by cyclopamine. Altogether, these results show that microparticles bearing Shh correct angiotensin II-induced hypertension and endothelial dysfunction in aorta through a mechanism associated with Shh-induced NO production and reduction of oxidative stress. These microparticles may represent a new therapeutic approach in cardiovascular diseases associated with decreased NO production.
微粒是细胞受刺激后产生的质膜小碎片。我们最近发现,音猬因子(Shh)存在于活化/凋亡的人T淋巴细胞产生的微粒中,并通过释放一氧化氮(NO)纠正内皮损伤。本研究调查携带Shh的微粒是否能纠正小鼠体内血管紧张素II诱导的高血压和内皮功能障碍。将雄性瑞士小鼠植入渗透微型泵,分别给予血管紧张素II(0.5 mg/kg/天)或氯化钠(0.9%)。在21天内每天测量收缩压和心率。微型泵植入7天后,小鼠静脉注射微粒(10 µg/ml)或腹腔注射Shh受体拮抗剂环杷明(10 mg/kg/每2天),持续一周。血管紧张素II使收缩压显著升高,但不影响心率。微粒逆转了血管紧张素II诱导的高血压,而环杷明则阻止了微粒的作用。微粒完全纠正了血管紧张素II灌注小鼠血管中乙酰胆碱和血流诱导的舒张功能障碍。环杷明处理完全阻止了微粒诱导的内皮功能改善。此外,单独的微粒不会改变主动脉中NO和超氧阴离子(O₂·⁻)的产生,但能显著增加血管紧张素II处理小鼠主动脉中NO的产生并减少O₂·⁻的产生,而这些作用被环杷明阻断。总之,这些结果表明,携带Shh的微粒通过与Shh诱导的NO产生和氧化应激降低相关的机制,纠正血管紧张素II诱导的高血压和主动脉内皮功能障碍。这些微粒可能代表了一种针对与NO产生减少相关的心血管疾病的新治疗方法。